Sodium-glucose co-transporter 2 inhibitors in heart failure: an updated evidence-based practical guidance for clinicians

Abstract The sodium-glucose co-transporter 2 (SGLT2) inhibitors have been shown to reduce risks of clinical events in patients with heart failure (HF), with early and sustained benefits regardless of ejection fraction, diabetic status, and care setting. As part and parcel of the modern foundational HF therapy, clinicians should be familiar with these drugs, in order to implement their use and limit the potential adverse effects. We present an up-to-date review of current evidence and a practical guide for the prescription of SGLT2 inhibitors in patients with HF, highlighting important elements for patient selection, treatment initiation, dosing, and problem solving.

[1]  Akshay S. Desai,et al.  Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Randomized Clinical Trial. , 2022, JAMA cardiology.

[2]  L. Calò,et al.  Sodium–glucose co-transporter 2 inhibitors for the treatment of cardio-renal syndrome , 2022, European heart journal supplements : journal of the European Society of Cardiology.

[3]  M. Landray,et al.  Empagliflozin in Patients with Chronic Kidney Disease , 2022, The New England journal of medicine.

[4]  Akshay S. Desai,et al.  Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction , 2022, JAMA cardiology.

[5]  G. Filippatos,et al.  Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure , 2022, JAMA cardiology.

[6]  Akshay S. Desai,et al.  Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. , 2022, The New England journal of medicine.

[7]  J. Ferreira,et al.  Use of sodium glucose co‐transporter 2 inhibitors in acute heart failure: a practical guidance , 2022, ESC heart failure.

[8]  Akshay S. Desai,et al.  SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials , 2022, The Lancet.

[9]  Lin Qiu,et al.  Effect of sodium-glucose cotransporter-2 inhibitors on blood pressure in patients with heart failure: a systematic review and meta-analysis , 2022, Cardiovascular Diabetology.

[10]  L. Calò,et al.  What proportion of patients with heart failure and preserved ejection fraction are eligible for empagliflozin? , 2022, Journal of cardiovascular medicine.

[11]  P. Schulze,et al.  Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF) , 2022, Circulation.

[12]  M. Link,et al.  2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2022, Circulation.

[13]  S. Pocock,et al.  Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled , 2022, European heart journal.

[14]  G. Filippatos,et al.  Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction. , 2022, Journal of the American College of Cardiology.

[15]  P. Ponikowski,et al.  The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial , 2022, Nature Medicine.

[16]  G. Filippatos,et al.  Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR‐Preserved trial , 2022, European journal of heart failure.

[17]  G. Sinagra,et al.  [ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: what's new?] , 2022, Giornale italiano di cardiologia.

[18]  H. Hillege,et al.  A Systematic Review and Network-Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction. , 2021, JACC. Heart failure.

[19]  P. Ponikowski,et al.  Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure. , 2021, Journal of the American College of Cardiology.

[20]  P. Ponikowski,et al.  Empagliflozin in Heart Failure with a Preserved Ejection Fraction. , 2021, The New England journal of medicine.

[21]  J. McMurray,et al.  2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. , 2021, European heart journal.

[22]  L. Calò,et al.  Sodium-glucose co-transporter-2 inhibitors eligibility in patients with heart failure with reduced ejection fraction. , 2021, International journal of cardiology.

[23]  P. Ponikowski,et al.  Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology , 2021, European journal of heart failure.

[24]  P. Ponikowski,et al.  Sodium–glucose co‐transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial , 2021, European journal of heart failure.

[25]  P. Ponikowski,et al.  Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. , 2021, JAMA cardiology.

[26]  P. Ponikowski,et al.  Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF. , 2021, JACC. Heart failure.

[27]  G. Filippatos,et al.  Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial , 2021, European heart journal.

[28]  Vinni Makin,et al.  The role of SGLT-2 inhibitors in managing type 2 diabetes , 2020, Cleveland Clinic Journal of Medicine.

[29]  F. Giorgino,et al.  Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk , 2020, Cardiovascular Diabetology.

[30]  Deepak L. Bhatt,et al.  Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. , 2020, The New England journal of medicine.

[31]  G. Filippatos,et al.  Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction , 2020, Circulation.

[32]  G. Filippatos,et al.  Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function , 2020, Circulation.

[33]  J. McMurray,et al.  Dapagliflozin in Patients with Chronic Kidney Disease. , 2020, The New England journal of medicine.

[34]  Akshay S. Desai,et al.  Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction , 2020, Circulation.

[35]  P. Ponikowski,et al.  Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. , 2020, The New England journal of medicine.

[36]  G. Filippatos,et al.  SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials , 2020, The Lancet.

[37]  McKenzie Ferguson,et al.  Prevention and Management of Genital Mycotic Infections in the Setting of Sodium-Glucose Cotransporter 2 Inhibitors , 2020, The Annals of pharmacotherapy.

[38]  D. DeMets,et al.  Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF , 2020, Circulation.

[39]  Akshay S. Desai,et al.  Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial. , 2020, JACC. Heart failure.

[40]  Akshay S. Desai,et al.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.

[41]  M. Vaduganathan,et al.  Practical Guide to Prescribing Sodium-Glucose Cotransporter 2 Inhibitors for Cardiologists. , 2019, JACC. Heart failure.

[42]  B. Vergès,et al.  Adverse effects and safety of SGLT-2 inhibitors. , 2014, Diabetes & metabolism.

[43]  Naoki Sato,et al.  The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. , 2014, Journal of the American College of Cardiology.

[44]  K. Johnsson,et al.  Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. , 2013, Journal of diabetes and its complications.

[45]  Hans L. Hillege,et al.  Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure , 2006, Circulation.